Research & Development Pipeline

RS Oncology’s development pipeline was initiated in early 2022 with the phase 1/2 MITOPE clinical trial

RSO-021

Local intrapleural administration via a catheter

Malignant Pleural Mesothelioma

Malignant Disease to the Lungs

Pleural Effusion

MITOPE-CLINICAL.png

RSO-021

Local intraperitoneal administration 

Malignant Peritoneal Mesothelioma

Ovarian Cancer

Local Peritoneal Cancers

RSO-023

Systemic Treatment

TBD